fate therapeutics stock price target

Their forecasts range from 6000 to 11600. FATE a clinical-stage biotechnology company are sliding in response to interim data from ongoing clinical trials with two of its new drug candidates.

Fate Fate Therapeutics Inc Stock Overview U S Nasdaq Barron S

The average twelve-month price target for Fate Therapeutics is 8722 with a high price target of 11600 and a low price target of 6000.

. 1y Target Est 8732 Fair Value is the appropriate price for the shares of a company based on its earnings and growth rate also interpreted as when PE Ratio Growth Rate. 7 2020 at 718 am. Stock Price Forecast The 19 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 9000 with a high estimate of 13500 and a low estimate of 4200.

Fate Therapeutics Inc. This suggests a possible upside of 2673 from the stocks current price. FATE now What analysts predict.

Volume today is light. The lowest target is 4242 and the highest is 14175. The average price target is 9300 with a high forecast of 14500 and a low forecast of 6000.

Shares of Fate Therapeutics NASDAQ. The company has an average price target. 47 rows Close price at the end of the last trading day Friday 6th May 2022 of the.

View FATE revenue estimates and earnings estimates as well as in-depth analyst breakdowns. Thats higher than the PS ratio of 9704 of US stocks. The average price target represents a 16855 upside from the last price of 3463.

According to the issued ratings of 9 analysts in the last year the consensus rating for Fate Therapeutics stock is Buy based on the current 2 hold ratings and 7 buy ratings for FATE. Price Price Target Lowest. 13000 The average price target includes all analyst analysis not just the most recent analysis presented in the chart.

Research and ratings by Barrons. Over the past 22 months FATEs average price target has gone up 5607. In the last 3 months 4 analysts have offered 12-month price targets for Fate Therapeutics.

5 Wall Street analysts that have issued a 1 year FATE price target the average FATE price target is 9360 with the highest FATE stock price forecast at 11500 and the lowest FATE stock price forecast at 7400. Based on analysts offering 12 month price targets for FATE in the last 3 months. 9 brokerages have issued twelve-month price targets for Fate Therapeutics shares.

FATEs pricesales ratio is 7242. According to 26 stock analysts the average 12-month stock price forecast for FATE stock is 9373 which predicts an increase of 28796. This chart shows the closing price for FATE.

FATE reports an average of 12469 for. So far 166777 shares have traded compared to average volume of 1318128 shares. AFTER HOURS 717 PM EDT 050622.

Fate Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day. On average they anticipate Fate Therapeutics stock price to reach 8722 in the next twelve months. Today 200 Day Moving Average is the resistance level 5459.

The share price of Fate Therapeutics Inc. On average analysts rate FATE stock as a buy. Click Here to get the full Stock.

The average price target is 000 with a high estimate of 000 and a low estimate of 000. Fate Therapeutics stock price target raised to 88 from 55 at Wedbush Dec. ET by Tomi Kilgore Fate Therapeutics stock price target raised to 65 from 40 at Truist.

The average Fate Therapeutics stock forecast represents a 13779 increase from the last price of 38689998626709. Revenue growth over the past 12 months for Fate Therapeutics Inc comes in at 7766 a number that bests 8918 of the US stocks were tracking. The 5 Wall Street analysts offering Fate Therapeutics stock forecast in the last 6 months have average price target of 920 with a high forecast of 1220 and a low forecast of 620.

Fate Therapeutics Inc FATE stock is trading at 6135 as of 1146 AM on Thursday Dec 30 a rise of 213 or 359 from the previous closing price of 5922. Wedbush Adjusts Fate Therapeutics Price Target to 77 From 74 Keeps Outperform Ratin. The minimum target price for Fate Therapeutics analysts is 90.

The Trend in the Analyst Price Target. The stock has traded between 5852 and 6228 so far today. Nasdaq AT CLOSE 400 PM EDT 050622.

129 rows This price target is based on 10 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months.

Hot Biotech Stocks To Watch After Sanofi S Acquisition Of Translate Bio